Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Drug

Alteogen Licenses ALT‑B4 Hyaluronidase to Tesaro for $285M Subcutaneous Dostarlimab Deal

Fineline Cube Jan 22, 2026
Company Deals

Eyebright Medical to Acquire Control of Delta Medical in $143 M Sports‑Medicine Deal

Fineline Cube Jan 22, 2026
Company Deals

Insilico Licenses NLRP3 Inhibitor ISM8969 to Hengtai in $64M CNS Drug Deal

Fineline Cube Jan 20, 2026
Company Deals

Shionogi Boosts ViiV Stake to 21.7% in $2.1 Billion Deal, Doubles Down on HIV Focus

Fineline Cube Jan 20, 2026
Company Deals Medical Device

EasyDiagnosis Bio to Acquire 51% of Ailex Medical in $5.1M Deal, Gains IVD Platform

Fineline Cube Jan 20, 2026
Company Drug Policy / Regulatory

Merson’s Bemejing Wins First CNMR “Overseas Version” Drug Price Certificate

Fineline Cube Jan 21, 2026
Company Deals Drug

Alteogen Licenses ALT‑B4 Hyaluronidase to Tesaro for $285M Subcutaneous Dostarlimab Deal

Fineline Cube Jan 22, 2026
Company Drug

Shanghai Pharma’s iNKT Cell Therapy B023 Gets NMPA Nod for Advanced Solid Tumors

Fineline Cube Jan 22, 2026
Company Deals

Akeso Biopharma and Shanghai Pharmaceuticals Collaborate on Liposarcoma Treatment

Fineline Cube Mar 8, 2023

China-based Akeso Biopharma (HKG: 9926) has announced a strategic collaboration agreement with compatriot firm Shanghai...

Company Deals

F-star Therapeutics’ Acquisition by invoX Pharma Cleared by CFIUS

Fineline Cube Mar 8, 2023

UK biotech F-star Therapeutics, Inc. (NASDAQ: FSTX) has announced that it has received clearance from...

Company Drug

Biocytogen’s YH008 Gets NMPA Approval for Phase I Study

Fineline Cube Mar 8, 2023

China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd has announced receiving approval from the China National Medical...

Company Deals

Heranova Closes $10M Seed Round for Women’s Health Solutions

Fineline Cube Mar 8, 2023

Heranova Lifesciences Holding, a provider of women’s health solutions, has announced the successful closure of...

Company Drug

Inmagene’s Tavalisse First Prescribed in China for ITP Treatment

Fineline Cube Mar 8, 2023

China-based Inmagene Biopharmaceuticals has announced that its in-licensed drug Tavalisse (fostamatinib) has been first prescribed...

Company Drug

AusperBio Initiates Phase I Trial for AHB-137 in New Zealand

Fineline Cube Mar 8, 2023

Sino-US liver therapy developer AusperBio has announced the initiation of the first cohort dosing in...

Policy / Regulatory

China’s Party and State Institutions Reshuffle: Key Changes for Healthcare and Finance

Fineline Cube Mar 8, 2023

The second plenary session of the 20th Communist Party of China (CPC) Central Committee has...

Company Drug

BrightGene’s Generic Halaven Approved for Marketing in China

Fineline Cube Mar 7, 2023

China-based BrightGene Bio-Medical Technology Co., Ltd (SHA: 688166) has received marketing approval from the National...

Company Deals

Abcam and MEDx Expand Strategic Partnership on Claudin 18.2 Diagnosis

Fineline Cube Mar 7, 2023

UK-based abcam (NASDAQ:ABCM) has announced a licensing agreement with China-headquartered MEDx Translational Medicine Co., Ltd,...

Company Drug

Inovio and ApolloBio Announce Positive Phase III Data for VGX-3100 Vaccine

Fineline Cube Mar 7, 2023

US-based Inovio Pharmaceuticals (NASDAQ: INO) and China-based ApolloBio Corp. (NEEQ:430187) have announced positive data from...

Policy / Regulatory

Sunshine Medical Procurement Platform Announces VBP Tender Results for Yangtze River Delta

Fineline Cube Mar 7, 2023

Shanghai’s Sunshine Medical Procurement All-In-One (SMPA) platform has revealed the resultant winning bids and spare...

Company Deals

Neo Modulus Secures Series B Funding for Regenerative Medical Device Development

Fineline Cube Mar 7, 2023

Neo Modulus, a developer of regenerative implantable medical devices based in Suzhou, has reportedly raised...

Company Drug

Takeda’s Exkivity Receives First Prescription in China with Innovative Payment Solutions

Fineline Cube Mar 7, 2023

Takeda Pharmaceutical Co., Ltd has announced the first prescription of its lung cancer therapy Exkivity...

Policy / Regulatory R&D

Pudong New Area Grants Duty-Free Import Qualifications to Seven Companies

Fineline Cube Mar 7, 2023

Seven companies have been awarded scientific and technological innovation duty-free import qualification designations by the...

Company Drug

Harbour BioMed’s Batoclimab Shows Positive Results in gMG Phase III Trial

Fineline Cube Mar 7, 2023

Harbour BioMed (HKG: 2142), a biotech company operating out of the United States, the Netherlands,...

Company Policy / Regulatory

BGI Group Subsidiaries Added to US Trade Blacklist by Commerce Department

Fineline Cube Mar 7, 2023

The US Department of Commerce (DOC)’s Bureau of Industry and Security (BIS) has added 37...

Company

Sanyou Biopharmaceuticals Expands Global Reach with New Cambridge Office

Fineline Cube Mar 6, 2023

Sanyou Biopharmaceuticals, a leading provider of biotech CRDMO services, is set to open a new...

Company Drug

Sanofi’s Dupixent Receives Priority Review for Prurigo Nodosa Treatment

Fineline Cube Mar 6, 2023

French pharmaceutical major Sanofi (NASDAQ: SNY) has announced that it has received priority review status...

Policy / Regulatory

China’s Premier Li Keqiang Highlights Economic and Social Advances in Annual Report

Fineline Cube Mar 6, 2023

Premier Li Keqiang delivered his annual Government Work Report at the “Two Sessions” meeting, which...

Company Drug

Eli Lilly’s Retevmo Launched in China by Innovent Biologics

Fineline Cube Mar 6, 2023

Eli Lilly & Co’s (NYSE: LLY) Retevmo (selpercatinib) has been officially launched in the Chinese...

Posts pagination

1 … 500 501 502 … 612

Recent updates

  • Alteogen Licenses ALT‑B4 Hyaluronidase to Tesaro for $285M Subcutaneous Dostarlimab Deal
  • Shanghai Pharma’s iNKT Cell Therapy B023 Gets NMPA Nod for Advanced Solid Tumors
  • Biokin’s Iza-bren ADC Receives NMPA Filing Acceptance for ESCC, World’s First EGFR×HER3 Bispecific
  • Kawin Technology Withdraws Hepatitis B Filing for Peginterferon Alfacon‑2 After NMPA Feedback
  • Eyebright Medical to Acquire Control of Delta Medical in $143 M Sports‑Medicine Deal
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals Drug

Alteogen Licenses ALT‑B4 Hyaluronidase to Tesaro for $285M Subcutaneous Dostarlimab Deal

Company Drug

Shanghai Pharma’s iNKT Cell Therapy B023 Gets NMPA Nod for Advanced Solid Tumors

Company Drug

Biokin’s Iza-bren ADC Receives NMPA Filing Acceptance for ESCC, World’s First EGFR×HER3 Bispecific

Company Drug

Kawin Technology Withdraws Hepatitis B Filing for Peginterferon Alfacon‑2 After NMPA Feedback

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.